Proximagen Neuroscience Plc, a King’s College London spin-out that recently raised £50 million on Britain’s junior stock market, has expanded its portfolio of CNS drug candidates with the acquisition of Cambridge Biotechnology Ltd. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
